- Home
- » Tags
- » Epoetin alfa
Top View
- List of Medications for PA FINAL 4.27.11.Xlsx
- John Hopkins Medicine Medicare Advantage Novologix Prior
- Table 1. Products Approved in FY 2009: New Drugs
- Coding Medical Necessity: Erythropoiesis Stimulating Agents (Esas)
- Concerns About the Use of Biosimilar Granulocyte Colony-Stimulating Factors for the Mobilization of Stem Cells in Normal Donors
- PROCRIT® (Epoetin Alfa)
- Table of Contents
- FDA Biosimilars and Interchangable Products
- The First Biosimilar, Zarxio, Was Approved by the Food and Drug Administration (FDA) in 2015
- State and Specialty Pharmacy Drug Reimbursement Rates
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Epoetin Alfa HEXAL, INN-Epoetin Alfa
- Geron Presentation
- Serve You Rx Prior Authorization Information and Drug List
- Amgen 2010 Annual Report and Financial Summary
- Highlights of Prescribing Information
- Lumicera Specialty Drug List
- Prior Authorization PDL Implementation Schedule
- Specialty Medications - Medical Benefit
- Pharmacy Drug List Changes THIRD QUARTER 2020 – COMMERCIAL PRODUCTS
- Specialty Drug List
- (12) Patent Application Publication (10) Pub. No.: US 2002/0052317 A1 Itri Et Al
- Background Dosing Information Drug Name Indication Dosing Regimen
- Self-Administered Specialty Drug List
- DARBEPOETIN ALFA, EPOETIN ALFA, and METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Policy Number: PHARMACY 080.29 T2 Effective Date: October 1, 2017
- Specialty Medications List Harness Health Pharmacy for Participants in the Medical Plan, Specialty Medications Are Prescribed to Treat Complex Diseases
- Pfizer Pipeline Snapshot 4
- The Use of Erythropoiesis-Stimulating Agents With
- Epogen /Procrit (Epoetin Alfa)
- The Biosimilar Landscape: an Overview of Regulatory Approvals by the EMA and FDA
- Reimbursement Criteria for Frequently Requested Drugs
- BCBSIL Medicaid: Specialty Pharmacy Code List
- Amgen Safety Net Foundation Offers Replacement Product for Physician-Administered Medications
- History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology
- Aranesp® (Darbepoetin Alfa)
- Specialty Drug List 08-24-10
- Kidney News Is Published by the American Society of Nephrology 1401 H Street, NW, Suite 900, Washington, DC 20005
- A Phase 3 Randomized Placebo-Controlled Trial of Darbepoetin Alfa in Patients with Anemia and Lower-Risk Myelodysplastic Syndromes
- A View Into Upcoming Specialty & Traditional Drugs
- Advantage MD Part B Prior Authorization List
- Labeling Package Insert
- A Phase I/II Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- Difference for ME.”
- STAT5 As a Key Protein of Erythropoietin Signalization
- GP2015 Biosimilar (Etanercept)
- EPOGEN Draft Patient Instructions for Use For
- Granulocyte and Erythropoietic Stimulating Proteins After High-Dose Chemotherapy for Myeloma
- The Impact of Biosimilar Competition in Europe Contents
- Drugs to Watch-2019
- View the Specialty Pharmacy 1199 SEIU Drug List
- Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
- Oncology Medicine Products: Medi-Cal ______Effective 11/2/2020, All Oncology Medications Will Require Prior Authorizations
- Epoetin Alfa-Xxxx (Procrit, Epogen, Retacrit)
- TEXAS MEDICAID Clinical Edit Prior Authorization Epoetin Alfa (EPOGEN)
- THE IMPACT of BIOSIMILAR COMPETITION in EUROPE October 2019
- Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/ Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
- Epoetin Alfa) for INJECTION
- Specialty Pharmacy Medication List
- Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion Kelly A
- Epoetin Alfa, Beta, Theta and Zeta; And, Darbepoetin Alfa) for Treating Cancer- Treatment Induced Anaemia (Including Review of TA142
- Blue Cross Medicare Advantage Specialty Pharmacy Code List
- Injectable Drugs Requiring Prior Authorization
- Downloads/Drugs/ of Biosimilars in Oncology
- Over-The-Counter Pharmacy Program
- ARANESP® (Darbepoetin Alfa)
- Epoetin Alfa (Epogen, Procrit) Reference Number: ERX.SPMN.136 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- April 25Th March April 2019 Clinical Rx Forum Newsletter.Pub
- Request Guidelines Submitting Your Request